期刊文献+

甲磺酸伊马替尼治疗慢性粒细胞白血病14例临床观察 被引量:5

暂未订购
导出
出处 《河北医学》 CAS 2010年第5期629-630,共2页 Hebei Medicine
  • 相关文献

参考文献3

  • 1Deininger MW,O'Brien SG,Ford JM,Druker BJ.Practical management of patients with chronic myeloid leukemia receiving imatinib[J].Clin Oncol,2003,21:1637-1647.
  • 2Hochhaus A,La Rosee P.Imatinib therapy in chronic myelogenous leukemia:strategies to avoid and overcome resistance[J].Leukemia,2004,18:1321-1331.
  • 3周励,王爱华,王黎,游建华,李军民,沈志祥.伊马替尼治疗慢性粒细胞白血病151例临床疗效及安全性观察[J].中华血液学杂志,2008,29(1):13-17. 被引量:35

二级参考文献6

  • 1Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 2004, 100:116-121.
  • 2Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta, 2001, 1551 : M11-18.
  • 3Socal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood, 1984, 63 : 789 -799.
  • 4O' Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003, 348 : 994-1004.
  • 5Droker BJ, O' Brien SG, Guilhot F, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355:2408-2417.
  • 6Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of phase 2 study. Blood, 2002, 99 : 1928-1937.

共引文献34

同被引文献36

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部